Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. More Details
Flawless balance sheet with limited growth.
Share Price & News
How has Paradigm Biopharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PAR is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: PAR's weekly volatility (8%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: PAR exceeded the Australian Biotechs industry which returned -10.9% over the past year.
Return vs Market: PAR underperformed the Australian Market which returned 35.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Paradigm Biopharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StParadigm Biopharmaceuticals (ASX:PAR) Shareholders Have Enjoyed A Whopping 650% Share Price Gain
2 months ago | Simply Wall StIs Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?
3 months ago | Simply Wall StWe're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn
Is Paradigm Biopharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PAR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PAR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PAR is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: PAR is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PAR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PAR is overvalued based on its PB Ratio (5.3x) compared to the AU Biotechs industry average (4.9x).
How is Paradigm Biopharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PAR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PAR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PAR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PAR's revenue (115.6% per year) is forecast to grow faster than the Australian market (4.9% per year).
High Growth Revenue: PAR's revenue (115.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PAR is forecast to be unprofitable in 3 years.
How has Paradigm Biopharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PAR is currently unprofitable.
Growing Profit Margin: PAR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PAR is unprofitable, and losses have increased over the past 5 years at a rate of 42.9% per year.
Accelerating Growth: Unable to compare PAR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PAR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.6%).
Return on Equity
High ROE: PAR has a negative Return on Equity (-31.22%), as it is currently unprofitable.
How is Paradigm Biopharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: PAR's short term assets (A$91.4M) exceed its short term liabilities (A$5.1M).
Long Term Liabilities: PAR's short term assets (A$91.4M) exceed its long term liabilities (A$772.9K).
Debt to Equity History and Analysis
Debt Level: PAR's debt to equity ratio (0.04%) is considered satisfactory.
Reducing Debt: PAR's debt to equity ratio has reduced from 0.3% to 0.04% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PAR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: PAR has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 32.7% each year.
What is Paradigm Biopharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PAR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PAR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PAR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PAR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PAR's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Paul Rennie (61 yo)
Mr. Paul John Rennie, BSc, MBM, Grad Dip Commercial Law, MSTC, serves as Executive Chairman at Paradigm Biopharmaceuticals Limited. He served as Interim Executive Chairman of Paradigm BioPharmaceuticals Lt...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD489.48K) is below average for companies of similar size in the Australian market ($USD713.55K).
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
Experienced Management: PAR's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Experienced Board: PAR's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Paradigm Biopharmaceuticals Limited's company bio, employee growth, exchange listings and data sources
- Name: Paradigm Biopharmaceuticals Limited
- Ticker: PAR
- Exchange: ASX
- Founded: 2014
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$472.130m
- Shares outstanding: 229.19m
- Website: https://www.paradigmbiopharma.com
- Paradigm Biopharmaceuticals Limited
- 500 Collins Street
- Level 15
Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/13 08:38|
|End of Day Share Price||2021/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.